Does your CE mark actually protect you outside the EU? Most sponsors assume it does — until their US arm hits an IDE requirement.

What happens when the MHRA stops accepting CE marking? The UKCA transition is closer than most compliance teams realise.

Can a single risk management file really travel across six jurisdictions? ISO 14971 might be the most underrated tool in global DHT compliance.

Why did a CE-marked wearable delay an oncology trial by six months? The answer involves three letters: IDE.

Is your DHT compliance plan actually a European compliance plan with a global-sized blind spot? Time to find out.

What is “timestamp drift,” and how can a few minutes of clock deviation invalidate your eCOA endpoint data?

Who actually owns the audit trail when participants, vendors, CROs, and sponsors all touch the data—but no one holds the full record?

How do Part 11 and GDPR collide in BYOD trials—and why does treating them as separate problems make both worse?

Could your eCOA vendor’s cloud routing create a cross-border GDPR violation you do not even know about?

What does a defensible pre-study BYOD governance plan look like—and why are most sponsors still building theirs after the inspection is announced?

Can consumer wearables like Fitbits generate regulatory-grade clinical trial data?

What risks arise when sponsors use consumer devices for endpoint collection?

How do regulators distinguish between wellness and medical use in trials?

What validation strategies make consumer devices acceptable for DHT endpoints?

Will future trials see broader adoption of consumer-grade wearables?

• Is your wearable sensor registered in EUDAMED — and does it need to be before 28 May 2026?

• What happens to your EU clinical trial if the device manufacturer doesn't have a Single Registration Number?

• Does your SaMD vendor know that EUDAMED registration is now a prerequisite for CE marking?

• Are you prepared for the Clinical Investigations module to go mandatory with zero voluntary phase?

• Could your next GCP inspection flag a EUDAMED registration gap you didn't know existed?

Why do some DHT-enabled trials clear regulatory review 3–6 months faster than others?

Is your compliance programme actually adding time to your timelines—or removing it?

Could stronger digital governance be your fastest route to regulatory approval?

Are your digital endpoints reducing uncertainty—or creating it?

Do regulators trust your DHT data before they even analyse it?

What makes a DHT truly “fit-for-purpose” in a clinical trial context?

How do verification and validation differ—and why does it matter?

What role does usability play in maintaining data integrity?

How can sponsors implement a risk-based approach to DHT qualification?

Which real-world lessons show how validation failures can derail trials?

Is your organization’s QMS built to manage devices, data, and endpoints together?

Would your DHT-derived evidence survive a multi-country audit?

Who in your team owns algorithm validation and version control?

How prepared are your vendors to meet ISO 13485 and MDR Article 22 obligations?

Can you trace every data point from patient to protocol—and back again?

How can sponsors eliminate “data breaks” across global DHT logistics networks?

What are regulators expecting in traceability documentation under MDR and GCP?

How can validated device reuse align with sustainability goals?

What role does blockchain play in improving audit traceability?

How do logistics systems influence data integrity in decentralized trials?

Are your DHTs classified and registered in every country where they’re used?

Have you appointed local importers and authorized representatives?

Do your vendor contracts cover data residency and cross-border transfers?

Can you demonstrate ALCOA++ traceability across countries and cloud regions?

Would your trial survive a multi-authority inspection tomorrow?

Are you certain your organization’s role under MDR or FDA law is correctly defined?

Have you appointed authorized importers or representatives for DHT deployments abroad?

Does your CRO or vendor contract include device vigilance responsibilities?

Are your system combinations documented under MDR Article 22 requirements?

If your DHT malfunctioned, could you prove who’s legally accountable?

Will your digital endpoints still hold up under regulatory scrutiny in 2026?

Could you explain your DHT data pipeline to an inspector—without guessing?

Are your algorithms governed as medical instruments or treated like IT tools?

Do you know which regulatory roles your organization already holds globally?

Is your QMS built for digital evidence—or for a pre-DHT world?

Can your audit trail reconstruct every DHT data transformation from source to submission?

Are firmware, algorithms, and databases synchronized under one ALCOA++ framework?

How do you manage data integrity across multiple vendors and jurisdictions?

Could your digital endpoints withstand an FDA or EMA data lineage audit?

Does your QMS explicitly integrate ALCOA++ and metadata provenance controls?

Are your current DHTs validated for analytical, clinical, and usability accuracy?

Who in your organization owns responsibility for device version control?

Would your DHT endpoints withstand an ALCOA++ traceability audit?

Have you mapped classification and importer roles for every deployment country?

Does your QMS integrate ISO 13485 and 14971 for device-level oversight?

What makes usability testing a regulatory requirement for DHTs?

How can poor usability compromise data integrity in decentralized trials?

What are the most effective methods for formative and summative usability testing?

How can sponsors ensure inclusivity and accessibility in usability testing?

How does usability engineering align with ISO 14971 risk management?

Have you validated every DHT used in your trial for analytical, clinical, and usability accuracy?

Are you certain of each device’s risk class in all deployment countries?

How do you control firmware and algorithm updates during studies?

Who in your organization owns usability validation and change control?

Would your DHT-derived endpoints survive regulatory scrutiny tomorrow?

How do sponsors avoid becoming “accidental manufacturers” when deploying wearables in trials?

What happens if a consumer-grade DHT fails to meet regulatory validation standards mid-trial?

Why does FDA treat DHT oversight in drug trials with the same rigor as device investigations?

How can poor sponsor oversight of DHTs derail regulatory submissions and cause trial failure?

What practical frameworks exist to help sponsors manage DHT responsibilities across borders?

Could your digital endpoints survive if an FDA inspector asked you to “show how this was generated”?

Are your device, algorithm, and data teams aligned—or are they assuming someone else is handling the risk?

Do your SOPs actually support decentralized trials, or are they relics from the site-centric era?

Would your DHT data hold up across review divisions, or would firmware drift and missing lineage collapse your evidence?

Is your organization prepared for the roles it already holds—sponsor, architect, system producer, and regulated partner?

Does your QMS include design-history and validation records for every DHT you use?

Are firmware, algorithms, and human-factors results governed under change control?

Can your vendor audits prove ISO 13485 and IEC 62304 compliance?

How do you integrate ALCOA++ and device traceability into your audit system?

Would your QMS withstand an FDA or MDR inspection focused on digital endpoints?

Are your current DHTs validated for analytical, clinical, and usability accuracy?

Who in your organization owns responsibility for device version control?

Would your DHT endpoints withstand an ALCOA++ traceability audit?

Have you mapped classification and importer roles for every deployment country?

Does your QMS integrate ISO 13485 and 14971 for device-level oversight?

What hidden operational traps are still tripping sponsors under the 2024 FDA DCT guidance?

How can sponsors maintain investigator oversight across decentralized models?

Why does device validation remain a recurring inspection finding?

What data integrity gaps most concern regulators in decentralized trials?

How can operational alignment with FDA guidance accelerate study approvals?